Medite Cancer Diagnostics Stock Net Income
| MDIT Stock | USD 0.0001 0.00 0.00% |
In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Medite Cancer Diagnostics, as well as the relationship between them.
Analyzing historical trends in various income statement and balance sheet accounts from Medite Cancer's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Medite Cancer's valuation are summarized below:Medite Cancer Diagnostics does not presently have any fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Medite |
Medite Cancer 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Medite Cancer's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Medite Cancer.
| 11/15/2025 |
| 02/13/2026 |
If you would invest 0.00 in Medite Cancer on November 15, 2025 and sell it all today you would earn a total of 0.00 from holding Medite Cancer Diagnostics or generate 0.0% return on investment in Medite Cancer over 90 days. Medite Cancer is related to or competes with Gilead Sciences, Sanofi ADR, Amgen, Merck, and Novo Nordisk. Medite Cancer Diagnostics, Inc. operates as a medical technology company More
Medite Cancer Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Medite Cancer's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Medite Cancer Diagnostics upside and downside potential and time the market with a certain degree of confidence.
Medite Cancer Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Medite Cancer's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Medite Cancer's standard deviation. In reality, there are many statistical measures that can use Medite Cancer historical prices to predict the future Medite Cancer's volatility.Medite Cancer Diagnostics Backtested Returns
We have found three technical indicators for Medite Cancer, which you can use to evaluate the volatility of the firm. The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Medite Cancer are completely uncorrelated.
Auto-correlation | 1.00 |
Perfect predictability
Medite Cancer Diagnostics has perfect predictability. Overlapping area represents the amount of predictability between Medite Cancer time series from 15th of November 2025 to 30th of December 2025 and 30th of December 2025 to 13th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Medite Cancer Diagnostics price movement. The serial correlation of 1.0 indicates that 100.0% of current Medite Cancer price fluctuation can be explain by its past prices.
| Correlation Coefficient | 1.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Medite Cancer Diagnostics reported net income of (6.81 Million). This is 102.0% lower than that of the Health Care Equipment & Supplies sector and 106.84% lower than that of the Health Care industry. The net income for all United States stocks is 101.19% higher than that of the company.
Medite Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medite Cancer's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Medite Cancer could also be used in its relative valuation, which is a method of valuing Medite Cancer by comparing valuation metrics of similar companies.Medite Cancer is currently under evaluation in net income category among its peers.
Medite Fundamentals
| Return On Equity | -0.74 | |||
| Return On Asset | -0.14 | |||
| Profit Margin | (0.65) % | |||
| Operating Margin | (0.49) % | |||
| Current Valuation | 7.44 M | |||
| Shares Outstanding | 86.72 M | |||
| Price To Earning | (2.47) X | |||
| Price To Book | 0.21 X | |||
| Price To Sales | 0.11 X | |||
| Revenue | 6.81 M | |||
| Gross Profit | 162 K | |||
| EBITDA | (6.19 M) | |||
| Net Income | (6.81 M) | |||
| Cash And Equivalents | 90 K | |||
| Total Debt | 4.91 M | |||
| Debt To Equity | 0.94 % | |||
| Current Ratio | 1.11 X | |||
| Book Value Per Share | 0.08 X | |||
| Cash Flow From Operations | (3.57 M) | |||
| Earnings Per Share | (0.11) X | |||
| Number Of Employees | 69 | |||
| Beta | 75.45 | |||
| Market Capitalization | 520.34 K | |||
| Total Asset | 15.96 M | |||
| Retained Earnings | (351 K) | |||
| Working Capital | (1.36 M) | |||
| Current Asset | 5.95 M | |||
| Current Liabilities | 7.31 M | |||
| Net Asset | 15.96 M |
About Medite Cancer Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medite Cancer Diagnostics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medite Cancer using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medite Cancer Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Medite Pink Sheet Analysis
When running Medite Cancer's price analysis, check to measure Medite Cancer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medite Cancer is operating at the current time. Most of Medite Cancer's value examination focuses on studying past and present price action to predict the probability of Medite Cancer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medite Cancer's price. Additionally, you may evaluate how the addition of Medite Cancer to your portfolios can decrease your overall portfolio volatility.